Gefimipsa 250mg Capsule is used in the treatment of non-small cell lung cancer. It is used in patients in which it has spread to other parts of the body, who have abnormal epidermal growth factor receptor (EGFR) genes, and who have not had previous treatment for cancer.

Gefimipsa 250mg Capsule should be taken in a dose as recommended by the doctor. You should continue to take it as long as your doctor advises for it. The duration of treatment varies according to your need and response to treatment. Your doctor may advice for regular monitoring of liver function while your taking this medicine.

Common side effects include diarrhea, dry skin, loss of appetite, and nausea. Drink plenty of fluids to reduce the risk of side effects. Inform your doctor if any of the side effects bother you or get worse. In case you develop ulceration in mouth, changes in your vision, or breathing difficulties than it is better to inform the doctor.

Women who are undergoing treatment should use effective contraception method. It is important to avoid pregnancy during the treatment and for a month after completing the course of medicine. Let your doctor also know about all the other medications you are taking.

Uses of Gefimipsa Capsule

Side effects of Gefimipsa Capsule

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Gefimipsa

Diarrhea
Dry skin
Loss of appetite
Nausea
Rash
Vomiting
Weakness
Weight loss
Eating disorder
Allergic reaction

How to use Gefimipsa Capsule

Take this medicine in the dose and duration as advised by your doctor. Gefimipsa 250mg Capsule may be taken with or without food, but it is better to take it at a fixed time.

How Gefimipsa Capsule works

Gefimipsa 250mg Capsule is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.

Safety advice

Alcohol

UNSAFE

It is unsafe to consume alcohol with Gefimipsa 250mg Capsule.

Pregnancy

CONSULT YOUR DOCTOR

Gefimipsa 250mg Capsule is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.

Breast feeding

CONSULT YOUR DOCTOR

Gefimipsa 250mg Capsule is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.

Driving

UNSAFE

Gefimipsa 250mg Capsule may cause side effects which could affect your ability to drive.

Kidney

CAUTION

Gefimipsa 250mg Capsule should be used with caution in patients with severe kidney disease. Dose adjustment of Gefimipsa 250mg Capsule may be needed. Please consult your doctor.

Liver

SAFE IF PRESCRIBED

Gefimipsa 250mg Capsule is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Gefimipsa 250mg Capsule may not be needed in these patients. Please consult your doctor.

What if you forget to take Gefimipsa Capsule?

If you miss a dose of Gefimipsa 250mg Capsule, skip it and continue with your normal schedule. Do not double the dose.

All substitutes

For informational purposes only. Consult a doctor before taking any medicines.

No substitutes found for this medicine

Quick tips

Gefimipsa 250mg Capsule helps treat non-small cell lung cancer that is locally advanced, or has spread to other areas of the body.
Take it with or without food, preferably at the same time each day.
Do not take antacids (to reduce the acid level of your stomach) 2 hours before or 1 hour after taking this medicine.
Diarrhea may occur as a side effect. Drink plenty of fluids and inform your doctor if it doesn't stop or if you find blood in your stools.
Use a reliable contraceptive method to prevent pregnancy while you are taking this medicine and for a month after you stop taking it.
Inform your doctor if you develop ulceration in your mouth, changes in your vision or if you experience a worsening cough, shortness of breath, or breathing difficulties while taking this medicine.
Your doctor may want you to have regular blood tests to monitor your liver function while you are having treatment with this medicine.

Fact Box

Chemical Class

Quinazolinamines

Habit Forming

Therapeutic Class

ANTI NEOPLASTICS

Action Class

Tyrosine Kinase Inhibitors (TKIs)

Interaction with drugs

Taking Gefimipsa with any of the following medicines can modify the effect of either of them and cause some undesirable side effects

Vinorelbine (Injection Route) Life-threatening

Do not consume Gefitinib with Vinorelbine. Concomitant use may cause a reduction in white blood cell levels.

Vinblastine (Injection Route) Severe

Concomitant use is not recommended. Please consult with your doctor. Gefitinib may raise blood levels of Vinblastine. Concurrent use may cause hairloss, drop in blood cell counts, ... More

Vincristine (Injection Route) Severe

Concomitant use is not recommended. Please consult with your doctor. Gefitinib may raise blood levels of Vincristine. Concurrent use may cause hairloss, drop in blood cell counts, ... More

Aprepitant (Injection Route) Moderate

Watch out for symptoms of Aprepitant side effects such as diarrhea, dry eye, vomiting, breathing problems, decreased appetite or rash and consult your doctor if you experience them... More

Bosentan (Oral Route) Moderate

Do not consume Gefitinib with Bosentan. If concurrent use is essential, your doctor may monitor your treatment and adjust the doses as per the observations. Bosentan may reduce blo... More

View all drug interactions

Patient concerns

I want to know the symptoms of cancer as I am a smoker

Dr. Vijay Sharnangat

Medical Oncology and Hematology

Symptoms for cancer depends upon which organ involved. For smokers , definitely chronic , they have possibility to develop lung cancer, head and neck cancers, oesophagus cancer, pancreatic cancer, stomach cancer and so more on. General symptoms would be like loss of appetite, weight loss, low grade fever in some cases, chronic cough for long time.

What is the purpose of Chemotherepy given at the time of radiotherapy in ca lung small cell carcinoma

Dr. Vijay Sharnangat

Medical Oncology and Hematology

This is given to enhance the therapeutic effect of radiation therapy which is curative for small cell lung cancer.

User feedback

Patients taking Gefimipsa 250mg Capsule

Once A Day

94%

Twice A Day

What are you using Gefimipsa Capsule for?

Non-small cel*

40%

Others

40%

Small cell lu*

20%

*Non-small cell lung cancer, Small cell lung cancer

How much was the improvement?

Poor

44%

Average

33%

Excellent

22%

What were the side-effects while using Gefimipsa 250mg Capsule?

No Side Effec*

67%

Nausea

33%

*No Side Effect

How do you take Gefimipsa Capsule?

With food

50%

With or witho*

50%

*With or without food

Please rate Gefimipsa 250mg Capsule on price

Expensive

50%

Average

50%

Related lab tests

Alpha-fetoprotein (AFP) L3 Fraction

Bcr-Abl Gene Translocation (Qualitative)

Bcr-Abl Gene Translocation (Quantitative)

Breast Cancer (CA 15.3/ ER/ PR)

Carcino Embryonic Antigen

Complete Blood Count

Peripheral Smear Examination

Thyroid Profile Free

Related ayurvedic ingredients

Olive oil

Fish Oil

Soybean

Want to share the information?

Disclaimer:

Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.

References

Chabner BA, Barnes J, Neal J, et al. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1734-35.
Chu E, Sartorelli AC. Cancer Chemotherapy. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. pp. 954-55.
Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 616-17.
Gefitinib. Luton, Bedfordshire: AstraZeneca UK Limited; 2009 [revised 23 Apr. 2018]. [Accessed 232 Jan. 2019] (online) Available from:
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. Gefitinib. [Updated 2018 Dec 3]. [Accessed 18 Feb. 2020] (online) Available from:
Central Drugs Standard Control Organisation (CDSCO). [Accessed 27 Mar. 2019] (online) Available from:
CiplaMed. Gefitinib [Prescribing Information]. [Accessed 06 Apr. 2024] (online) Available from: